Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Pilgrim's Pride (PPC) upgraded to Outperform from Market Perform at BMO Capital with analyst Kenneth Zaslow citing the management's implementation of a "successful execution" of its chicken strategy. 2. Beyond Meat (BYND) upgraded to Overweight from Neutral at JPMorgan while Campbell Soup (CPB) was upgraded to Neutral from Underweight. 3. Chemours (CC) upgraded to Positive from Neutral at Susquehanna with analyst Don Carson saying he thinks end-user destocking of TiO2 appears to have run its course and he views the company as the prime beneficiary of an upturn in industry volumes in 2020. 4. AbbVie (ABBV) upgraded to Overweight from Neutral at Piper Jaffray with analyst Christopher Raymond saying while he remains negative on the company's decision to acquire Allergan (AGN), he believes that a bottom on the stock has been found around $66. 5. CACI (CACI) upgraded to Outperform from Neutral at Credit Suisse with analyst Robert Spingarn saying in an uncertain macro environment, he likes a defensive name that can support a multi-year story of organic growth, margin expansion, and M&A optionality, all while offering an attractive valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

Latest data shows the largest indicative borrow rate increases among liquid option names include: Luminar Technologies (LAZR) 24.73% +5.07, Spring Valley Acquisition Corp (SMR) 22.39% +3.98, ImmunityBio (IBRX) 74.40% +3.41, Lucid Group (LCID) 33.21% +2.31, ALTC Acquistion Corp (ALCC) 5.21% +1.04, Beyond Meat (BYND) 59.00% +0.68, Energy Fuels (UUUU) 2.23% +0.37, SoundHound AI (SOUN) 13.94% +0.32, Microvision (MVIS) 14.83% +0.31, and Cassava Sciences (SAVA) 21.42% +0.27.

AbbVie announced positive topline results from LEVEL UP, an open-label, efficacy assessor-blinded head-to-head Phase 3b/4 study that evaluated the efficacy and safety of upadacitinib versus dupilumab in adults and adolescents with moderate-to-severe atopic dermatitis who had an inadequate response to systemic therapy or when use of those therapies was inadvisable. In the LEVEL UP study, upadacitinib showed superior efficacy versus dupilumab in the primary endpoint, demonstrating that a significantly higher proportion of patients simultaneously achieved both a 90% or greater reduction in Eczema Area and Severity Index and a Worst Pruritus Numerical Rating Scale of 0 or 1 at Week 16.

Consensus $20.31. Raises FY24 revenue view to $7.5B-$7.6B from $7.3B-$7.5B, consensus $7.4B.

Reports Q3 revenue $1.94B, consensus $1.86B. "CACI's outstanding performance reflects the continued successful execution of our strategy. We're winning and delivering in the marketplace with differentiated capabilities, exceptional business development, and program execution," said John Mengucci, CEO. "Our third quarter results were strong across the board, including double-digit organic growth, margin expansion, $3.5 billion of awards, and record backlog. Our performance enables us to again raise fiscal year 2024 revenue and earnings guidance. We remain confident in our ability to drive long-term growth, increase free cash flow, and generate value for our customers and our shareholders."

Stifel analyst Bert Subin raised the firm's price target on CACI to $430 from $390 and keeps a Buy rating on the shares. CACI "remains on a roll, winning various new contracts and task orders," says the analyst, who adds CACI remains the firm's top picks in the core government services sector. The firm has increased estimates for FY24, but "more so for FY25," to reflect new awards with additional upside potential from intel spending, the analyst tells investors.